06 July 2023
06 July 2023
The much-anticipated draft guidance on DCTs is here, however, it might have missed several important points on delegation and data management.
Top-line results after the induction phase (primary endpoint at week ten) are expected in the following months.
The study intends to enrol a total of 188 patients from Europe and the US early in the third quarter of this year.
BP02 showed a similar clinical response compared to Herceptin.
The study is anticipated to start enrolling patients in the upcoming weeks.
ADL018 is a biosimilar candidate to Novartis’ Xolair (omalizumab), which had global drug sales of $3.8bn in 2022.
The study intends to assess the efficacy and safety of Tinlarebant in patients with GA associated with Dry AMD.
The University of Kentucky Sanders-Brown Center on Aging is the first activated site for enrolment.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
